New horizons in adjuvants for vaccine development

被引：503

作者：

Reed, Steven G. ^{[1
]}

Bertholet, Sylvie ^{[1
]}

Coler, Rhea N. ^{[1
]}

Friede, Martin ^{[2
]}

机构：

[1] Infect Dis Res Inst, Seattle, WA 98104 USA

[2] WHO, CH-1211 Geneva 27, Switzerland

来源：

TRENDS IN IMMUNOLOGY | 2009年 / 30卷 / 01期

关键词：

HEPATITIS-B-VACCINE; INFLUENZA VACCINE; IMMUNE-RESPONSES; ALUMINUM-HYDROXIDE; MALARIA VACCINE; CROSS-PRESENTATION; DENDRITIC CELLS; T-CELLS; IMMUNOGENICITY; RECOMBINANT;

D O I：

10.1016/j.it.2008.09.006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Over the last decade, there has been a flurry of research on adjuvants for vaccines, and several novel adjuvants are now in licensed products or in late stage clinical development. The success of adjuvants in enhancing the immune response to recombinant antigens has led many researchers to re-focus their vaccine development programs. Successful vaccine development requires knowing which adjuvants to use and knowing how to formulate adjuvants and antigens to achieve stable, safe and immunogenic vaccines. For the majority of vaccine researchers this information is not readily available, nor is access to well-characterized adjuvants. In this review, we outline the current state of adjuvant research and development and how formulation parameters can influence the effectiveness of adjuvants.

引用

页码：23 / 32

页数：10

共 100 条

[1] Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens [J].